Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963772 | 0.99 | AKR1B1 (0.33) | GALR1ALDH1A1AKR1B1PDE7A | |
| SCHEMBL5964122 | 0.86 | POLB (0.35) | GALR1ALDH1A1AKR1B1 | |
| SCHEMBL5963589 | 0.85 | SLC6A4 (0.38) | GALR1ALDH1A1AKR1B1PDE7A | |
| SCHEMBL5963305 | 0.82 | SLC6A3 (0.39) | ALDH1A1AKR1B1PDE7A | |
| SCHEMBL5001155 | 0.81 | PTGS2 (0.37) | — | |
| SCHEMBL5004858 | 0.81 | AKR1B1 (0.33) | GALR1AKR1B1 | |
| SCHEMBL5964210 | 0.80 | AKR1B1 (0.34) | ALDH1A1AKR1B1 | |
| SCHEMBL6820261 | 0.80 | FPR2 (0.35) | ALDH1A1AKR1B1PDE7A | |
| SCHEMBL5900937 | 0.80 | RECQL (0.33) | ALDH1A1 | |
| SCHEMBL5007459 | 0.79 | FPR2 (0.32) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1497317-B1 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060167268-A1 | Growth hormone secretagogues | ELI LILLY AND COMPANY, PATENT DIVISION, (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050240001-A1 | 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167268-A1 | Growth hormone secretagogues | GHSR, GHRHR, CRH | GALR1 139/4885ALDH1A1 4382/4885AKR1B1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.